Large-Scale Prospective Virtual Screening Using a Co-Folding-Rescoring Workflow for NPM1-TYK2 Inhibitor Discovery

Conventional large-scale structure-based virtual screening typically relies on fixed-receptor docking, in which ligand poses are sampled against a predefined receptor conformation. Protein-ligand co-folding models can instead generate candidate complex conformations by jointly modeling ligand placement and local receptor-ligand structural adaptation. Although recent benchmark studies have demonstrated the promise of AlphaFold3-like approaches for retrospective virtual screening, their practical application to target-specific, large-scale prospective screening with experimental validation remains limited. Here, we developed and prospectively applied a co-folding-rescoring workflow for NPM1-TYK2 inhibitor discovery. Using an in-house set of 4608 compounds experimentally annotated in Ba/F3-NPM1-TYK2 cells, we evaluated 13 pipelines combining AlphaFold 3, Protenix, Glide, or AutoDock Vina pose generation with scoring functions or confidence metrics. AlphaFold 3 followed by AutoDock Vina rescoring achieved the numerically highest BEDROC value, closely comparable to Protenix + Vina, and was selected for screening a commercial library of more than 300,000 compounds. AF3-generated complex conformations were subsequently rescored with Vina and prioritized by physicochemical assessment, clustering, and binding-mode inspection. Of 30 compounds tested experimentally, FV13 was identified as a cell-active primary hit, with a TYK2 kinase IC50 of 21.70 μM and a Ba/F3-NPM1-TYK2 cellular IC50 of 17.07 μM. Subsequent analog exploration yielded TX14, exhibiting an approximately 9.4-fold improvement in biochemical TYK2 inhibitory potency (IC50 = 2.31 μM). Additional selectivity profiling and Western blot analyses further characterized these compounds and indicated attenuation of downstream STAT5 phosphorylation at higher concentrations. Together, these findings demonstrate the feasibility of integrating co-folding, empirical rescoring, and target-specific experimental data for large-scale prospective hit discovery.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-03
DOI
https://doi.org/10.3390/ijms27219864
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Large-Scale Prospective Virtual Screening Using a Co-Folding-Rescoring Workflow for NPM1-TYK2 Inhibitor Discovery

Tingjun Hou, S Y Chen, Peichen Pan, Rubi Hu et al.
International Journal of Molecular Sciences
Computational Drug Discovery Methods
article

Large-Scale Prospective Virtual Screening Using a Co-Folding-Rescoring Workflow for NPM1-TYK2 Inhibitor Discovery

Tingjun Hou, S Y Chen, Peichen Pan, Rubi Hu, Xin Chai, Wanglin Qu, Odin Zhang, Huating Wang, Weixin Tian, Jiale Zheng, Yu Kang, Hui Zhang, Xujun Zhang, Yuanyi Ye, Dan Li
article en

Abstract

Conventional large-scale structure-based virtual screening typically relies on fixed-receptor docking, in which ligand poses are sampled against a predefined receptor conformation. Protein-ligand co-folding models can instead generate candidate complex conformations by jointly modeling ligand placement and local receptor-ligand structural adaptation. Although recent benchmark studies have demonstrated the promise of AlphaFold3-like approaches for retrospective virtual screening, their practical application to target-specific, large-scale prospective screening with experimental validation remains limited. Here, we developed and prospectively applied a co-folding-rescoring workflow for NPM1-TYK2 inhibitor discovery. Using an in-house set of 4608 compounds experimentally annotated in Ba/F3-NPM1-TYK2 cells, we evaluated 13 pipelines combining AlphaFold 3, Protenix, Glide, or AutoDock Vina pose generation with scoring functions or confidence metrics. AlphaFold 3 followed by AutoDock Vina rescoring achieved the numerically highest BEDROC value, closely comparable to Protenix + Vina, and was selected for screening a commercial library of more than 300,000 compounds. AF3-generated complex conformations were subsequently rescored with Vina and prioritized by physicochemical assessment, clustering, and binding-mode inspection. Of 30 compounds tested experimentally, FV13 was identified as a cell-active primary hit, with a TYK2 kinase IC50 of 21.70 μM and a Ba/F3-NPM1-TYK2 cellular IC50 of 17.07 μM. Subsequent analog exploration yielded TX14, exhibiting an approximately 9.4-fold improvement in biochemical TYK2 inhibitory potency (IC50 = 2.31 μM). Additional selectivity profiling and Western blot analyses further characterized these compounds and indicated attenuation of downstream STAT5 phosphorylation at higher concentrations. Together, these findings demonstrate the feasibility of integrating co-folding, empirical rescoring, and target-specific experimental data for large-scale prospective hit discovery.

International Journal of Molecular SciencesVol. 27(21)
Zhejiang Normal University (CN), Chinese University of Hong Kong (HK), Jinhua Academy of Agricultural Sciences (CN), Zhejiang University (CN)
Openalex Percentile: Top 16%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon